Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States



Survival: 24.3 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
   
Drugs:
Country: United States
   
City/State/Province: Houston, Texas
   
Hospital: The University of Texas M. D. Anderson Cancer Center
   
Journal: Link
   
Date: 7/2012

Description:
Patients:
This phase 2 study involved 38 mantle-cell lymphoma patients. The median patient age was 64 years and 92% were male.

Treatment:
Patients were treated with the biologic therapy agents lenalidomide and rituximab (a monoclonal antibody for CD20 that causes the immune system to attack tumor cells).

Toxicities:
The most severe toxicities were of grade 4 and included blood clots. Grade 3 fatigue and abdominal pain, as well as grade 2 infection, were reported.

Results:
The median overall survival was 24.3 months.

Support:
This study was supported by the pharmaceutical company Celegene.

Correspondence: Dr. Michael Wang; email: miwang@mdanderson.org

E-mail to a Friend Email Physician More Information